Allogeneic Melanoma Lysate Vaccines

  • Malcolm S. Mitchell
Part of the Cancer Drug Discovery and Development book series (CDD&D)


Active specific immunotherapy, more commonly known as the use of “vaccines” for the treatment of cancer, has found its greatest use in melanoma. The ease of establishing primary cultures of melanoma cells, and cell lines, has enabled the study of immune responses toward melanoma more readily than most other tumors. The availability of these cell lines has facilitated the production of allogeneic vaccines for treatment.


Human Leukocyte Antigen Human Leukocyte Antigen Class Resected Stage Bacille Calmette Guerin Active Specific Immunotherapy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Old U. Cancer immunology: the search for specificity-G. H. A. Clowes Memorial lecture. Cancer Res 1981; 41:361–375.Google Scholar
  2. 2.
    Kan-Mitchell J, Imam A, Kempf RA, Taylor CR, Mitchell MS. Human monoclonal antibodies directed against melanoma tumor-associated antigens. Cancer Res 1986; 46:2490–2496.PubMedGoogle Scholar
  3. 3.
    Kan-Mitchell J, Mitchell MS. Human monoclonal antibodies. Prog Clin Biol Res 1989; 288:85–94.PubMedGoogle Scholar
  4. 4.
    Formenti SC, Mitchell MS, Taylor CR, Lipkin M, Jernstrom PH, Kan-Mitchell J. Reactivity of a human monoclonal antibody against carcinomas and other lesions of the colon. Cancer Immunol Immunother 1989; 28:296–300.PubMedCrossRefGoogle Scholar
  5. 5.
    Van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254:1643–1647.PubMedCrossRefGoogle Scholar
  6. 6.
    Topalian SL, Hom SS, Kawakami Y, Mancini M, Schwartzentruber DJ, Zakut R, Rosenberg SA. Recognition of shared melanoma antigens by human tumor-infiltrating lymphocytes. J Immunother 1992; 12:203–206.PubMedCrossRefGoogle Scholar
  7. 7.
    Berd D, Maguire HJ, Mastrangelo MJ. Potentiation of human cell-mediated and humoral immunity by low-dose cyclophosphamide. Cancer Res 1984; 44:5439–5443.PubMedGoogle Scholar
  8. 8.
    Morton DL, Foshag LJ, Hoon DS, Nizze JA, Famatiga E, Wanek LA, Chang C, Davtyan DG, Gupta RK, Elashoff R. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine [published erratum appears in Ann Surg 1993; 217:309]. Ann Surg 1992; 216:463–482.Google Scholar
  9. 9.
    Mitchell MS, Jakowatz J, Harel W, Dean G, Stevenson L, Boswell WD, Groshen S. Increased effectiveness of interferon-alfa 2b following active specific immunotherapy for melanoma. J Clin Oncol 1994; 12:402–411.PubMedGoogle Scholar
  10. 10.
    Elliott GT, McLeod RA, Perez J, Von Eschen KB. Interim results of a phase II multicenter clinical trial evaluating the activity of a therapeutic melanoma vaccine (theraccine) in the treatment of disseminated malignant melanoma. Semin Surg Onc 1993; 9:264–272.Google Scholar
  11. 11.
    Sondak VK, Liu PY, Tuthill RJ, Kempf RA, Unger JM, Sosman JA, Thompson JA, Weiss GR, Redman BG, Jakowatz JG, Noyes RD, Flaherty LE. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 2002; 20:2058–2066.PubMedCrossRefGoogle Scholar
  12. 12.
    Hersey P. Vaccinia viral lysates in treatment of melanoma. In: Mitchell MS, ed. Biological approaches to cancer treatment: biomodulation. New York: McGraw-Hill, 1992:302–325.Google Scholar
  13. 13.
    Kirkwood JM, Ernstoff ME. Potential applications of the interferons in oncology. Semin Oncol 1986; 13:48–56.PubMedGoogle Scholar
  14. 14.
    Vaishampayan U, Abrams J, Darrah D, Jones V, Mitchell MS. Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha. Clin Cancer Res 2002; 8:3696–3701.PubMedGoogle Scholar
  15. 15.
    Mitchell MS. Perspective on allogeneic melanoma lysates in active specific immunotherapy. Semin Oncol 1998; 25:623–635.PubMedGoogle Scholar
  16. 16.
    Mitchell MS, Kan-Mitchell J, Kempf RA, Harel W, Shau H, Lind S. Active specific immunotherapy of melanoma. Phase I trial of allogeneic melanoma lysates and a novel adjuvant. Cancer Res 1988; 48: 5883–5893.PubMedGoogle Scholar
  17. 17.
    Mitchell MS, Harel W, Kempf RA, Kan-Mitchell J, Boswell WD, Hu E, Dean G, Stevenson L. Activespecific immunotherapy for melanoma. J Clin Oncol 1990; 8:856–869.PubMedGoogle Scholar
  18. 18.
    del Guercio MF, Sidney J, Hermanson G, Perez C, Grey HM, Kubo RT, Sette A. Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype. J Immunol 1995; 154: 685–693.PubMedGoogle Scholar
  19. 19.
    LeMay LG, Kan-Mitchell J, Goedegebuure P, Harel W, Mitchell MS. Detection of human melanomareactive CD4+ HLA class I-restricted cytotoxic T cell clones with long-term assay and pretreatment of targets with interferon-gamma. Cancer Immunol Immunother 1993; 37:187–194.PubMedCrossRefGoogle Scholar
  20. 20.
    Mitchell MS, Harel W, Groshen S. Association of HLA phenotype with clinical response to active specific immunotherapy of melanoma. J Clin Oncol 1992; 10:1158–1168.PubMedGoogle Scholar
  21. 21.
    Sosman JA, Unger JM, Liu PY, Flaherty LE , Park MS, Kempf RA, Thompson JA, Terasaki PI, Sondak VK. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine:impact of HLA class I antigen expression on outcome. J Clin Oncol 2002; 20:2067–2075.PubMedCrossRefGoogle Scholar
  22. 22.
    Ruiter DJ, Mattijssen V, Broecker EB, Ferrone S. MHC antigens in human melanomas. Semin Cancer Biol 1991; 2:35–45.PubMedGoogle Scholar
  23. 23.
    Mitchell MS, Harel W, Kan-Mitchell J, LeMay LG, Goedegebuure P, Huang X-Q, Hofman F, Groshen S. Active specific immunotherapy of melanoma with allogeneic cell lysates: rationale, results and possible mechanisms of action. In: Bystryn J-C, Ferrone S, Livingston P, eds. Specific immunotherapy of cancer with vaccines. Ann N Y Acad Sci 1993; 690:153–166.Google Scholar
  24. 24.
    Murray DR, Cassel WA, Torbin AH, Olkowski ZL, Moore ME. Viral oncolysate in the management of malignant melanoma. II. Clinical studies. Cancer 1977; 40:680–686.PubMedCrossRefGoogle Scholar
  25. 25.
    Wallack M, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D, Robinson WA, Flaherty L, Richards JM, Bartolucci AA, Rosen L. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 1998; 187:69–77.PubMedCrossRefGoogle Scholar
  26. 26.
    Chan AD and Morton DL. Active immunotherapy with allogeneic tumor cell vaccines: present status. Semin Oncol 1998; 25:611–622.PubMedGoogle Scholar
  27. 27.
    Mitchell MS, Kan-Mitchell J, Morrow PR, Darrah D, Jones VE, Mescher MF. Phase I trial of large multivalent immunogen (LMI) derived from melanoma lysates, in patients with disseminated melanoma. Submitted for publication, 2003.Google Scholar

Copyright information

© Humana Press Inc. 2004

Authors and Affiliations

  • Malcolm S. Mitchell

There are no affiliations available

Personalised recommendations